Intensive care unit-related fluconazole use in Spain and Germany: patient characteristics and outcomes of a prospective multicenter longitudinal observational study
- Background: Candida spp. are a frequent cause of nosocomial bloodstream infections worldwide. Objective: To evaluate the use patterns and outcomes associated with intravenous (IV) fluconazole therapy in intensive care units in Spain and Germany. Patients and methods: The research reported here was a prospective multicenter longitudinal observational study in adult intensive care unit patients receiving IV fluconazole. Demographic, microbiologic, therapy success, length of hospital stay, adverse event, and all-cause mortality data were collected at 14 sites in Spain and five in Germany, from February 2004 to November 2005. Results: Patients (n = 303) received prophylaxis (n = 29), empiric therapy (n = 140), preemptive therapy (n = 85), or definitive therapy (n = 49). A total of 298 patients (98.4%) were treated with IV fluconazole as first-line therapy. The treating physicians judged therapy successful in 66% of prophylactic, 55% of empiric, 45% of preemptive, and 43% of definitive group patients. In the subgroup of 152 patients with proven and specified Candida infection only, 32% suffered from Candida specified as potentially resistant to IV fluconazole. The overall mortality rate was 42%. Conclusion: Our study informs treatment decision makers that approximately 32% of the patients with microbiological results available suffered from Candida specified as potentially resistant to IV fluconazole, highlighting the importance of appropriate therapy.
Verfasserangaben: | Heimo Wissing, Jose Ballus, Tobias Michael BingoldORCiDGND, Gonzalo Nocea, Karl J. Krobot, Peter Kaskel, Ritesh N. Kumar, Panagiotis Mavros |
---|---|
URN: | urn:nbn:de:hebis:30:3-267894 |
DOI: | https://doi.org/10.2147/IDR.S38945 |
ISSN: | 1178-6973 |
Pubmed-Id: | https://pubmed.ncbi.nlm.nih.gov/23386790 |
Titel des übergeordneten Werkes (Englisch): | Infection and drug resistance |
Verlag: | Dove Medical Press |
Verlagsort: | Albany, Auckland |
Dokumentart: | Wissenschaftlicher Artikel |
Sprache: | Englisch |
Datum der Veröffentlichung (online): | 29.01.2013 |
Datum der Erstveröffentlichung: | 29.01.2013 |
Veröffentlichende Institution: | Universitätsbibliothek Johann Christian Senckenberg |
Datum der Freischaltung: | 13.02.2013 |
Freies Schlagwort / Tag: | Candida; antifungal agents; fungal infection; therapy |
Jahrgang: | 6 |
Seitenzahl: | 11 |
Erste Seite: | 15 |
Letzte Seite: | 25 |
Bemerkung: | © 2013 Wissing et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
HeBIS-PPN: | 331369621 |
Institute: | Medizin |
DDC-Klassifikation: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Sammlungen: | Universitätspublikationen |
Lizenz (Deutsch): | Creative Commons - Namensnennung 3.0 |